<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157906">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01692093</url>
  </required_header>
  <id_info>
    <org_study_id>CCRG_KM110329</org_study_id>
    <nct_id>NCT01692093</nct_id>
  </id_info>
  <brief_title>KM110329 in Adult Patients With Atopic Dermatitis</brief_title>
  <official_title>KM110329 in Adult Patients With Atopic Dermatitis : a Randomised, Double-blind, Placebo-controlled, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St Mary's Hospital, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Gangdong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine clinical efficacy and safety of KM110329 for
      Atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blind, placebo-controlled, multicenter trial will be conducted at the
      Seoul St.Mary's Hospital, at Chung-ang University hospital, and at Kyung Hee University
      Hospital at Gangdong.

      Participants fulfilling eligibility criteria will be selected. Enrolled participants will be
      randomly allocated to two parallel groups: the KM110329 and placebo arms.

      Each participant will be examined for signs and symptoms of Atopic dermatitis before and
      after taking functional food.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>SCORAD index</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>SCORing Atopic Dermatitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DLQI</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Dermatology Life Quality Index</description>
  </secondary_outcome>
  <other_outcome>
    <measure>TEWL</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Transepidermal Water Loss</description>
  </other_outcome>
  <other_outcome>
    <measure>hydration in the stratum corneum</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>hydration in the stratum corneum</description>
  </other_outcome>
  <other_outcome>
    <measure>KiFDA-HM-AD</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation endpoint for clinical trial of herbal medicinal products about atopic dermatitis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>KM110329</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive KM110329 for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo drug for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>KM110329</intervention_name>
    <description>KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health</description>
    <arm_group_label>KM110329</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18 to 65 years

          -  Individuals who diagnosed Atopic dermatitis according to the criteria of Hanifin and
             Rajka

          -  Individuals who mild to moderate atopic dermatitis (objective SCORADâ‰¤40)

          -  Written informed consent for participation in the trial

        Exclusion Criteria:

          -  Severe skin disease other than Atopic dermatitis

          -  Secondary infection with bacteria, fungi, and virus

          -  Uncontrolled hypertension (SBP &gt; 145 mmHg or DBP &gt; 95 mmHg)

          -  Severe liver disability (2.5-fold the normal high range value for ALT, AST)

          -  Severe renal disability (sCr &gt; 2.0mg/dl)

          -  Women who are pregnant, lactating, planning a pregnancy or women of child-bearing age
             who do not agree to proper contraception

          -  Use of oral steroids, oral antibiotic or other immunosuppressants within the past 4
             weeks

          -  Treated by systemic photochemotherapy within past 4 weeks

          -  History of drug abuse

          -  Hypersensitivity to Rubi Fructus, Houttuyniae Herba, Rehmanniae Radix, Betulae
             Platyphyllae Cortex

          -  Use of other investigational products within the past two months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SEONG GYU KO, M.D.(DKM)</last_name>
    <role>Study Director</role>
    <affiliation>Kyung Hee University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyung Hee University</name>
      <address>
        <city>Seoul</city>
        <zip>130-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHUNHOO CHEON, M.D.(DKM)</last_name>
      <phone>82-2-961-9278</phone>
      <email>pm.thehoo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Seong-Gyu Ko</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>SCORAD</keyword>
  <keyword>Atopic dermatits</keyword>
  <keyword>Skin health</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
